Skip to content

Comparative study of Sanger sequencing and specific panel high-throughput sequencing for detection of NF1 pathogenic mutations in Han Chinese

Comparative study of Sanger sequencing and specific panel high-throughput sequencing for detection of NF1 pathogenic mutations in Han Chinese

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-16009551
Enrollment
Unknown
Registered
2016-10-23
Start date
2016-10-28
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurofibromatosis

Interventions

Gold Standard:
Index test:

Sponsors

Shanghai 9th People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 45 Years

Inclusion criteria

Inclusion criteria: In accordance with the 1987 NIH clinical criteria for diagnosis of NF1 patients Patient with neurofibromatosis 1 according the NIH criteria : 1. Six or more café au lait macules over 15 mm in greatest diameter in postpubertal individuals; 2. Two or more neurofibromas of any type or one plexiform neurofibroma; 3. Freckling in the axillary or inguinal regions (Crowe's sign); 4. Optic glioma; 5. Two or more Lisch nodules (iris hamartomas); 6. A distinctive osseous lesion such as sphenoid dysplasia or thinning of long bone cortex with or without pseudoarthrosis; 7. A first-degree relative (parent, sibling, or offspring) with NF1 by the above criteria; 8. The criteria are met in an individual if two or more of the features listed are present. Healthy people 1. Diagnosed during 2011 to 2018; 2. male and female aged 10 years old - 45 years old; 3. the blood routine index in normal range.

Exclusion criteria

Exclusion criteria: 1) at the same time with other infectious diseases; 3) abnormal blood routine index; 4) participating in other clinical trials of patients; 5) researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
Pathogenic mutation site;

Countries

China

Contacts

Public ContactXiaojie Hu

Shanghai 9th People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine

hxjie2002@hotmail.com+86 18017681268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026